Graft-versus-Host Disease Models
Creative Animodel provides graft-versus-host disease (GvHD) models to conduct preclinical drug screening, efficacy and safety assessment, as well as biological studies. Our company has collected and validated a wide range of modeling protocols used for pharmaceutical industry. Both consistency and accuracy of our animal models are guaranteed. Cooperating with Creative Animodel will be your best choice for drug research and development.
What Is GvHD?
Graft-versus-host disease, abbreviated as GvHD, is a medical complication following allograft. GvHD commonly occurs after a bone marrow transplant, a stem cell transplant, or a blood transfusion if the blood products have not been treated with radiation or a pathogen reduction system. The underlying principle of GvHD is that immune cells in the donated tissue recognize the recipient as foreign and attack the host’s body cells. Different from transplant rejection that occurs when the host rejects the graft, GvHD occurs when the graft rejects the host. In the clinical setting, GvHD is divided into acute (AGvHD) and chronic (CGvHD) forms.
Figure 1. The initiation and amplification of GVHD by alloantigen presentation. Naive donor T cells migrate into recipient lymph nodes and GVHD target organs. They encounter recipient alloantigen presented by recipient APCs and/or by recipient nonhematopoietic APCs. Hereafter, donor T cells proliferate and differentiate into Th1 and Th17 cells and induce GVHD in the target tissues, particularly the GI tract. (Koyama, et al. 2016)
The standard treatment in AGvHD and CGvHD is intravenously administered glucocorticoids, such as prednisone. The glucocorticoids are used to suppress the T-cell-mediated immunoreaction on the host tissues, but the risks of infections and cancer relapse are increased in high doses. Cyclosporine and tacrolimus are two effective substances in GvHD treatment, which can inhibit calcineurin and block dephosphorylation of the transcription factor of activated T cells. The US FDA has approved ibrutinib to treat CGvHD in August 2017.
GvHD Models at Creative Animodel
Preclinical evidence of GvHD is most frequently generated in mice, canine, and non-human primates (NHP), which helps to improve the success rate of hematopoietic stem cell transplantation. Creative Animodel can establish AGvHD and CGvHD models by different strategies in various animal species. Our GvHD models include but are not limited to those shown in Table 1.
Table 1. AGvHD and CGvHD models provided by Creative Animodel
|AGvHD models||CGvHD models|
|Allobone marrow transplant models|
Xenogeneic transplant models
Antigen-specific transgenic TCR models
Models involving both autoantibodies and scleroderma
Defective thymic function models
Creative Animodel has a team of scientists specialized in animal models generation and preclinical in vivo drug trials. As your desirable partner, we will deliver high-quality data and reliable assessment results to help you further optimize your drug candidates. If you have any needs, please don’t hesitate to contact us.
1. Koyama, M.; Hill, G. R. Alloantigen presentation and graft-versus-host disease: fuel for the fire. Blood, 2016, 127(24): 2963-2970.
2. Schroeder, M. A.; DiPersio, J. F. Mouse models of graft-versus-host disease: advances and limitations. Disease models & mechanisms, 2011, 4(3): 318-333.